Background: Transarterial chemoembolization (TACE) is recommended as a treatment for unresectable
Introduction
Transarterial chemoembolization (TACE) is the standard of care for intermediate stage hepatocellular carcinoma (HCC) in patients that are not candidates for surgical resection or tumour ablation. 1, 2 Population-based data demonstrates that TACE is the most common oncological treatment performed for HCC among Medicare patients in the United States. 3 Review of the Scientific Registry of Transplant Recipients (SRTR) data on liver transplantation for HCC also demonstrates that TACE is the most common bridging therapy offered to >70% of patients on a waiting list in the US. 4 Current practice guidelines from the American Association for the Study of Liver Disease (AASLD) recommend TACE 'as "first" line non-curative therapy for non-surgical patients with large/ multifocal HCC who do not have vascular invasion or extrahepatic spread. . . .' 5, 6 The AASLD's recommendation, however, only apply to Child-Pugh class A patients. 5, 6 The AASLD further states that 'patients with advanced liver disease (Child-Pugh class B or C) and/or clinical symptoms of end-stage cancer should not be considered for these treatments as they have an increased risk of liver failure and death.' 5, 6 The AASLD practice guidelines for TACE were based upon a heterogeneous collection of clinical studies, many of which utilized non-selective lobar chemoembolization approaches. 7, 8 Often, there is significant 'innocent bystander' hepatocyte necrosis as a complication of non-selective lobar chemoembolization approaches. 9, 10 There is increasing recognition that selective HCC chemoembolization approaches, where only the hepatic arterial branches directly supplying the HCC are treated, may be performed with minimal (non-targeted) collateral damage to adjacent uninvolved hepatic parenchyma. 10 The development of microcatheters and the application of super-selective embolization techniques have prompted the University of Alabama at Birmingham (UAB) Liver Tumor Board to increasingly offer TACE to select cirrhotic patients with compromised liver function.
The purpose of this study was to measure the safety and efficacy of TACE procedures performed as first-line therapy in cirrhotic patients with Child-Pugh class B or C compromised liver function. The outcomes in the Child-Pugh B or C patients were compared with a contemporaneous group of Child-Pugh A cirrhotic patients treated similarly. Our hypotheses were (i) TACE can be performed safely in Child-Pugh B or C cirrhotic patients, (ii) there will be no difference in HCC tumour necrosis in ChildPugh A compared with Child-Pugh B or C patients and (iii) there will be equivalent post-TACE survival in Child-Pugh A compared with Child-Pugh B or C patients.
Methods
Ethics approval for this study was obtained from the University of Alabama Institutional Review Board (Protocol #X100310006). A retrospective chart review was performed for all patients receiving a TACE at UAB between January 2008 and June 2012. Patients were identified from an internal TACE database that is used for clinical purposes.
Patient population
Patients were diagnosed with HCC according to the AASLD criteria either by biopsy or by the presentation of classic HCC radiological features of a >2-cm hypervascular lesion arising in the setting of cirrhosis with arterial phase enhancement and portal venous phase washout. 11 The decision to offer TACE to patients with HCC was made by a multi-disciplinary liver tumour board at UAB including medical oncologists, surgeons, hepatologists and interventional radiologists. Candidacy for TACE in Child-Pugh A patients was determined by established AASLD practice guidelines. 5, 6 Select Child-Pugh class B and C cirrhotic patients were offered TACE if they had an ECOG functional status of 0 or 1, limited tumour burden and medically controlled symptoms of hepatic decompensation. There was no absolute cut-off model for end-stage liver disease (MELD) score, Child-Pugh score, bilirubin, international normalized ratio, etc. However, most Child-Pugh class B and C patients offered TACE had a hyperbilirubinemia that was predominantly indirect and/or hypoalbuminemia out of proportion to the overall clinical assessment. Patients could have ascites although the ascites needed to be controlled with diuretics; an active need for paracentesis was a contraindication. Patients could also have a history of encephalopathy but this needed to be controlled medically without evidence of recent hospitalizations. Child-Pugh class B or C patients were not offered TACE if they had medically refractory ascites or poorly controlled encephalopathy.
A list of all patients treated with TACE between January 2008 and June 2012 was generated from the UAB Interventional Radiology procedures electronic database (n = 348). Patients were excluded if they had a non-HCC tumour type (n = 45) and if the TACE procedure performed was not the 'first' TACE intervention (n = 113) (Fig. 1 ). HCC tumours that had previously been treated operatively or with another locoregional therapy such as radiofrequency ablation or external beam radiotherapy were excluded from the study. Patients taking chemotherapeutic agents before and/or after the procedure were included in the study. All patients were felt to have cirrhosis based upon a combination of platelet counts and radiographical criteria.
Imaging
Patients were only included if they had high-quality three phase or four phase computed tomography imaging or liver protocol magnetic resonance imaging (MRI) within 75 days prior to and after the TACE procedure.
HCC tumour assessment and post-TACE tumour necrosis quantification
After an extensive training period, two second year medical students (D.D. and M.B.) independently reviewed CT and MRI studies performed before and after TACE for all patients. The body radiology fellow (J.Z.) taught the medical students about the basics of multiphasic CT and outlined a consistent approach to calculating axial tumour dimensions and identifying post-TACE tumour necrosis. After these teaching sessions, the fellow and medical students jointly worked through 20 patients together. The medical students, body fellow and senior staff then reviewed 20 patients independently and the results were reviewed to verify consistency. The medical students then reviewed all CT imaging independently. The medical students saved the marked images indicating caliper and contrast enhancement measurements. The UAB body radiology fellow independently reviewed all CT and MRI studies and confirmed all measurements. A staff radiologist (K.S.) with 19 years of experience in body imaging confirmed all quantitative data. When evaluating the cross-sectional imaging, the assessors were blinded to the Child-Pugh class and MELD score.
The tumour response was assessed via the modified response evaluation criteria in solid tumours (mRECIST). Using CT or MRI studies obtained prior to the procedure, a pre-TACE tumour size was determined. The measurements were then repeated on CT or MRI studies obtained after the procedure. Consistent with mRECIST criteria, only axial images were used for tumour size measurements. Electronic calipers were used to measure the longest diameter of each tumour and the widest perpendicular measurement in the same image for use in calculating crosssectional tumour diameter.
In 2008, the AASLD modified the National Cancer Institute RECIST criteria to unify assessment of a radiographical response for HHC. 12 The modified RECIST criteria response is based on residual arterial enhancement rather than purely tumour shrinkage measured by the greatest diameter of the lesion. Response data are presented for the largest lesion only, herein referred to as the index lesion. There are four categories of tumour response according to mRECIST: complete response, partial response, stable disease or progressive disease. 12 A complete response is defined as the disappearance of tumour arterial enhancement. A partial response is defined as at least a 30% decrease in the diameter of arterial enhancement. Stable disease is defined as a response that did not fall into the partial response or progressive disease category. Progressive disease is defined as growth of at least 20% of the sum of the longest diameter of the lesions.
TACE protocol
The decision to offer TACE as loco-regional oncological therapy for patients with HCC was made at the UAB multidisciplinary liver tumour board. There were two general approaches to TACE: single or oligo-HCC tumours were generally treated with a Lipodiolbased targeted TACE whereas multifocal HCC tumours were treated with drug eluting beads (DEBS). Lipodiol-based TACE consisted of HCC embolization with a mixture of Lipodiol, 50 mg of Doxorubicin and 400-μm Embozene® microspheres (Celonova, San Antonio, TX, USA). DEBS TACE consisted of either LC beads (Biocompatibles UK Ltd, Farnham, UK) or QuadraSpheres® expanding microspheres (BioSphere Medical, Roissy en France, France). These beads were eluted with 50 mg Doxorubicin.
Statistical analysis
Patient demographics, clinical history, laboratory data and crosssectional imaging characteristics were collected. Pre-TACE imaging CT and MRI variables included tumour location (peripheral versus central, right lobe versus not), number of lesions, size of tumours and total diameter of three of the largest tumours in the case of multifocal HCC. Data collected from post-TACE CT and MRI imaging included HCC tumour necrosis as measured according to mRECIST criteria. 12 To allow common statistical procedures, the analysis was restricted to examination of the index HCC tumour that was defined as the largest tumour (if more than one tumour per patient had been used in the analysis, the common assumption of independent data observations would have been violated). A two sample t-test was used to compare means between the groups. The primary analytic approach for dichotomous variables utilized chi-square analyses. Kaplan-Meier curves were constructed to evaluate patient survival. Survival probabilities were analysed with the log-rank test. For all inferences, the probability of a Type I error (α) was set to 0.05. All analyses were conducted using SAS 9.2 (SAS Inc., Cary, NC, USA).
Results

Patient demographics
There were 100 TACE patients in the Child-Pugh class A group and 90 TACE patients in the Child-Pugh class B or C group who underwent TACE as an initial locoregional therapy. The ChildPugh class A group was older than the Child-Pugh B or C group (63.4 ± 10.5 compared with 59.6 ± 6.9, P = 0.0038). There were no differences in gender or race between the groups. There were more Child-Pugh class A patients with hepatitis B (9.0% versus 2.2%, P < 0.05), fewer patients with hepatitis C (48.0% versus 62.2%, P < 0.05) and a trend towards fewer patients with alcoholic liver disease (21.0% versus 32.2%, P < 0.1) compared with the ChildPugh B or C patients. A platelet count over 100 × 10 9 /l was observed in 69.0% of the Child-Pugh class A patients whereas a platelet count less than 100 × 10 9 /l was observed in 74.4% of the Child-Pugh class B/C patients (P < 0.0001). As expected, the lab-MELD score was significantly lower in the Child-Pugh class A patients compared with the Child-Pugh class B or C patients (8.7 ± 1.9 versus 13.4 ± 3.8, P < 0.0001). (Table 1) Tumour characteristics Significant demographic differences in tumour characteristics were observed between the Child-Pugh class A and B/C groups. Although the alpha-fetoprotein levels and tumour number were not different, the Child-Pugh class A patients had a larger tumour diameter (5.5 ± 3.2 versus 3.8 ± 2.0, P < 0.001) and larger summed diameters of the three largest tumours (7.5 ± 5.2 versus 5.2 ± 2.5, P = 0.003). In addition, more of the Child-Pugh class A patients were on Sorafenib within 90 days before or after TACE compared with Child-Pugh class B/C patients (39.0% versus 25.6%, P < 0.05) ( Table 1) .
TACE procedures
There were no significant differences in the number of TACE procedures performed in each group. A single TACE procedure was performed in 56.0% of the Child-Pugh class A patients and in 57.5% of the Child-Pugh class B/C patients. Two TACE procedures were performed in 33% of each group and approximately 10% of each group had three or more TACE procedures. Furthermore, there was no significant difference in the number of repeat TACE procedures performed within 6 months of the 'first' TACE procedure (24.0% A versus 20.7% B/C, P = 0.59). There also were no significant differences in the use of Lipiodol or DEBS between the groups. Although non-selective (lobar) TACE was uncommon (15/190, 8%), more non-selective TACE procedures were performed in the Child-Pugh class A patients compared with the Child-Pugh B/C patients (12.2% versus 3.3%, P = 0.02) ( Table 1) .
HCC tumour necrosis
There were no significant differences in TACE-induced HCC tumour necrosis between groups as quantified by mRECIST criteria. There was a higher proportion of the Child-Pugh class B/C group that demonstrated a complete radiographical response after TACE; however, the difference was not statistically significant (Fig. 2) . On subgroup analysis, there also were no significant differences in TACE-induced HCC tumour necrosis when comparing selective and non-selective TACE approaches (P = 0.88) Changes in hepatic function post-TACE Measures of liver function were recorded immediately prior to TACE and 1 month post-TACE. The difference in liver function measurements (pre-to post-TACE) was compared between the Child-Pugh class A and B/C groups. (Table 2 ) There was a slight, but statistically significant, increase in the Child-Pugh and MELD scores in the Child-Pugh A group compared with the Child-Pugh B/C group (Child-Pugh score: Δ+0.35 points versus Δ 0.0 points, P < 0.001; MELD score: Δ+0.71 points vs. Δ-0.01 points, P < 0.001). Similarly, there was a slight, but statistically significant decrease in the serum albumin in the Child-Pugh A group compared with the Child-Pugh B/C group (Δ-0.21 versus Δ-0.05 g/dl, P < 0.001). In contrast, there were no significant differences in total bilirubin, INR, creatinine, ascites or encephalopathy measurements between the Child-Pugh groups.
Subgroup analyses were performed comparing changes in liver function measurements as a function of TACE vehicle. No difference in liver function measurements was observed between patients treated with Lipiodol or DEBS. (Table 3 ) Subgroup analyses were also performed comparing changes in liver function measurements as a function of the TACE approach. No difference in liver function measurements was observed between selective and non-selective TACE approaches.
Survival
There was no 30-day mortality observed in either the Child-Pugh class A or the Child-Pugh class B/C groups. There were 90-day mortalities observed in two Child-Pugh class A and four ChildPugh class B/C patients (P = 0.90). Kaplan-Meier curves were constructed for each group (Fig. 3) . The survival curves separate at 3 months and reach maximal separation by 12 months. Superior survival was observed in the Child-Pugh class A group compared with the Child-Pugh class B/C group (log rank test, P = 0.03). The median survival estimate from the Kaplan-Meier curves was 21.9 months in the Child-Pugh class A compared with 13.7 months in the Child-Pugh class B/C group.
A Cox proportional hazards model was constructed to identify pre-TACE variables associated with post-TACE mortality in the Child-Pugh class B/C group. Only total tumour diameter (hazard ratio 1.26, 95% confidence interval 1.10-1.44, P < 0.001) was independently associated with post-TACE mortality in ChildPugh class B/C patients.
Discussion
The most important finding demonstrated in this study is that TACE can be performed safely in select patients with compromised liver function. No peri-procedural or 30-day mortalities were observed in either group, in contrast to the 10-20% mortality risk reported in an older study of non-Child-Pugh class A patients 13 that is frequently quoted in TACE reviews.
14 Changes in liver function were minimally worse in both groups after TACE. The difference in liver function measurements (pre-to post-TACE) was comparable between the Child-Pugh class A and B/C groups. Other previous studies have also documented no significant longterm worsening of liver function after TACE in cirrhotics. 15 The group of Child-Pugh B/C patients, however, is undoubtedly a selected subgroup of patients with compromised liver function in spite of an average lab MELD score that was five points higher than the Child-Pugh class A patients. Piscaglia et al. 16 demonstrates the inverse association between rising Child-Pugh scores and candidacy for TACE. While TACE may be a safe oncological intervention in select patients with Child-Pugh class B/C cirrhosis, previous studies have demonstrated that ChildPugh classification is significantly associated with post-TACE complications, 17 and the development of radiocontrast-induced nephropathy post-TACE. 18 Many studies have also confirmed that Child-Pugh class is significantly associated with survival post-TACE. [19] [20] [21] [22] [23] Other studies have reported on the individual components of the Child-Pugh scoring system. Dr Yao's group measured risk factors associated with irreversible hepatotoxicity in a large series of TACE patients treated at the University of California, San Francisco, and reported bilirubin>4 mg/dl, elevated INR, albumin<2 g/l, creatinine>2 mg/dl, large ascites, encephalopathy and a MELD score > 19 were independently associated with mortality. 24 Another important observation from this study is that equivalent tumour necrosis can be achieved in Child-Pugh class B/C patients. Worsening liver disease per se does not appear to affect the process of administering chemoembolization materials and inducing tumour necrosis. This study demonstrated a practice pattern of preferentially performing selective TACE in ChildPugh class B/C patients. Repeat TACE was performed in 42.5% of the Child-Pugh class B/C patients. It is important to note, however, the tumour selection bias present in the Child-Pugh class B/C patients. The oncological indications for TACE were more conservative than those for Child-Pugh class A patients as evidenced by smaller HCC tumours and a reduced total tumour diameter in Child-Pugh class B/C patients. In contrast, the indications for TACE in Child-Pugh class A were much more liberal given the preserved liver function.
Perhaps the biggest question raised by this study is whether or not the median survival of 13 months observed in the Child-Pugh B/C patients represents improved survival in response to life prolonging therapy compared with best medical care? Unfortunately this study was not able to answer this question because we have no untreated group for comparison. It is also hard to identify studies in the literature to use as a reasonable survival comparison owing to the heterogeneity of patients in the different studies. Approximately 70-100% of patients enrolled in HCC TACE studies only include Child-Pugh class A patients 14 and meta-analyses have been unable to quantify the effect of Child-Pugh class and survival owing to outcomes data not being stratified by Child-Pugh class. 8 In addition, most chemotherapy trials only include patients that have failed or are not candidates for locoregional therapy. 25, 26 It is tempting to use the index Sorafenib study 25 as a frame of reference, which demonstrated a median survival of 10.7 months in the treated Child-Pugh class A patients (although these patients either had failed or were not candidates for locoregional therapies). The follow-up GIDEON trial (observational Sorafenib) demonstrates a median survival of 3.6 months in Child-Pugh class B and 2.1 months in Child-Pugh class C patients. 26 The historical survival in the control group (best supportive care) of one of the randomized clinical trials that served to demonstrate the survival benefit of TACE was 6 months. 27 A more recent study of Child-Pugh B patients demonstrated a median survival of 8 months, although survival differed greatly in Child-Pugh class B7, B8 and B9 patients. 16 Given these clinical outcomes as a relative comparison, it seems that a median survival of 13 months in a group of Western patients with both advanced liver disease and advanced HCC probably represents a survival benefit.
Our clinical observation is that there is considerable disparity in the chemoembolization techniques and outcomes from centre to centre. Review of the literature confirms these observations based upon the large variability in outcomes reported for TACE trials. 14 The use of selective or non-selective (lobar) approaches is operator dependent and varies with the skill set of the interventionist. There is also a growing trend away from traditional Lipiodol to DEBS as the platform for delivering locoregional chemoembolization material. 28 Selective and sub-selective approaches were used for many of the Child-Pugh class B/C patients in this study, especially for patients with compromised liver function. There are always some 'innocent bystander' (non-cancerous hepatocyte) deaths with TACE. 9, 10 Our approach is to use a 'smart-bomb' (selective) approach, as opposed to a'nuclear-bomb'(non-selective) approach to minimize non-cancerous hepatocyte death in an effort to preserve existing liver function. We would caution against nonselective TACE especially in Child-Pugh class B/C patients with HCC although, admittedly, our concerns are theoretical and not based upon the results of our study or a personal experience of higher complication rates as we generally try to avoid this approach (as evidenced by a 3.3% frequency of non-selective TACE in ChildPugh B/C patients). Notably, the 10-20% mortality after TACE in Child-Pugh class B/C patients reported by Vetter et al. in 1991 involved non-selective approaches. 13 As with all retrospective studies, this report has several limitations. First is the selection bias observed in the Child-Pugh class B/C patients both from liver function and tumour burden perspectives. Therefore, our findings are not applicable to all patients with significant liver dysfunction. Second, we commonly performed selective TACE procedures whereas it is our impression that many TACE procedures performed nationwide are actually non-selective lobar approaches, which may limit the generalizability of the study. Finally, we do not have a control group of Child-Pugh class B/C that was not treated with TACE for comparison. Our liver tumour clinic evaluates many HCC patients with compromised liver dysfunction for which no treatment is recommended. However, we chose to not compare to this palliative group owing to the selection bias between those patients that were recommended therapy and those not recommended therapy.
In conclusion, this study of 90 patients undergoing TACE procedures as the first-line locoregional therapy in select Child-Pugh class B/C patients demonstrates that this intervention can be performed relatively safely with equivalent tumour necrosis results when compared with Child-Pugh class A patients. Post-TACE survival outcomes were inferior compared with the Child-Pugh class A patients, but TACE intervention in this select group 
